HotSpot announces $65M Series B, as Nimbus pioneers look to keep up in a crowding field
In the decade since Nimbus Therapeutics built a company around computation and little-known phenomena like allosteric regulation, the industry has brimmed with algorithm companies and even a few chasing those same targets. Still, a couple of the old leaders think they can keep an edge.
“We’re very proud to have pioneered the field,” Gerry Harriman told Endpoints News. “And we’re also very proud to say our portfolio is full of targets that have allosteric inhibitors really for the first time that has ever been described.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.